ISPOR - Pharmacoeconomic Analysis Of Afatinib As 1st-Line Treatment Of Metastatic Non-Small Cell Lung Cancer With Del19 Mutation Of Egfr Gene

Full Text

Pharmacoeconomic Analysis Of Afatinib As 1st-Line Treatment Of Metastatic Non-Small Cell Lung Cancer With Del19 Mutation Of Egfr Gene

Abstract

Authors

D Belousov V Gorbunova S Orlov E Afanasieva

Back to Volume 18, Issue 7

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now